Hyug Moo Kwon Selected Research

NFATC Transcription Factors

1/2021	PARP1-mediated PARylation of TonEBP prevents R-loop-associated DNA damage.
8/2020	Tonicity-responsive enhancer-binding protein promotes stemness of liver cancer and cisplatin resistance.
1/2020	TonEBP in dendritic cells mediates pro-inflammatory maturation and Th1/Th17 responses.
10/2019	Transcriptional Regulator TonEBP Mediates Oxidative Damages in Ischemic Kidney Injury.
10/2019	Tonicity-responsive enhancer binding protein (TonEBP) regulates TNF-α-induced hypothalamic inflammation.
1/2019	Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis.
1/2018	Tonicity-Responsive Enhancer-Binding Protein Mediates Hyperglycemia-Induced Inflammation and Vascular and Renal Injury.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hyug Moo Kwon Research Topics

Disease

10	Inflammation (Inflammations) 12/2020 - 06/2015
3	Neoplasms (Cancer) 01/2021 - 01/2019
2	Diabetic Nephropathies (Diabetic Nephropathy) 01/2020 - 05/2006
2	Insulin Resistance 01/2020 - 01/2016
2	Hepatocellular Carcinoma (Hepatoma) 01/2020 - 01/2019
2	Autoimmune Diseases (Autoimmune Disease) 01/2020 - 01/2020
2	Hyperglycemia 10/2019 - 01/2018
1	Metabolic Diseases (Metabolic Disease) 01/2022
1	Obesity 01/2022
1	Memory Disorders (Memory Loss) 12/2020
1	Liver Neoplasms (Liver Cancer) 08/2020
1	Rheumatoid Arthritis 01/2020
1	Bacterial Infections (Bacterial Infection) 01/2020
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020
1	Multiple Sclerosis 01/2020
1	Hypertension (High Blood Pressure) 01/2020
1	Atherosclerosis 01/2020
1	Acute Kidney Injury (Acute Renal Failure) 01/2020
1	Hypoxia (Hypoxemia) 10/2019
1	Anorexia 10/2019
1	Hyperthermia 10/2019
1	Neoplasm Metastasis (Metastasis) 01/2019
1	Fibrosis (Cirrhosis) 01/2019
1	Liver Diseases (Liver Disease) 01/2019
1	Carcinogenesis 01/2019
1	Sepsis (Septicemia) 01/2016
1	Type 2 Diabetes Mellitus (MODY) 01/2016
1	Rupture 11/2013
1	Cysts 12/2012
1	Renal Cell Carcinoma (Grawitz Tumor) 05/2006

Drug/Important Bio-Agent (IBA)

7	NFATC Transcription FactorsIBA 01/2021 - 01/2018
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2006
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 05/2006
1	Adrenergic Agents (Adrenergic Drugs)IBA 01/2022
1	CatecholaminesIBA 01/2022
1	Histones (Histone)IBA 01/2022
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2022
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 01/2021
1	CamptothecinIBA 01/2021
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 12/2020
1	Cisplatin (Platino)FDA LinkGeneric 08/2020
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2020
1	MutagensIBA 01/2020
1	SaltsIBA 01/2020
1	Adenosine Triphosphate (ATP)IBA 10/2019
1	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 10/2019
1	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2019
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2019
1	Heme Oxygenase-1IBA 01/2019
1	Neutralizing AntibodiesIBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	endotrophinIBA 01/2019
1	Imatinib Mesylate (Gleevec)FDA Link 01/2016
1	CeruleninIBA 01/2016
1	Insulin (Novolin)FDA Link 06/2015
1	Cathepsin BIBA 11/2013
1	Transcription Factors (Transcription Factor)IBA 05/2006
1	Aldehyde Reductase (Aldose Reductase)IBA 05/2006
1	L-Iditol 2-Dehydrogenase (L Iditol 2 Dehydrogenase)IBA 05/2006
1	Glucose (Dextrose)FDA LinkGeneric 05/2006

Therapy/Procedure

1	Nephrectomy 05/2006